New treatments in ulcer healing and wound infection.

  • Edmonds M
  • Bates M
  • Doxford M
 et al. 
  • 2

    Readers

    Mendeley users who have this article in their library.
  • N/A

    Citations

    Citations of this article.

Abstract

This review examines several of the recently introduced wound care products that have been put forward as treatment modalities for the diabetic foot ulcer. Discussed are the results of clinical trials with the platelet-derived growth factor, becaplermin, the tissue-engineered products Dermagraft and Apligraf, and Hyaff which is an ester of hyaluronic acid. In patients with an infected foot ulcer, encouraging results were obtained with the granulocyte-colony stimulating factor, Filgrastim.

Author-supplied keywords

  • Collagen
  • Collagen: therapeutic use
  • Diabetic Foot
  • Diabetic Foot: therapy
  • Foot Ulcer
  • Foot Ulcer: therapy
  • Granulocyte Colony-Stimulating Factor
  • Granulocyte Colony-Stimulating Factor: physiology
  • Granulocyte Colony-Stimulating Factor: therapeutic
  • Humans
  • Platelet-Derived Growth Factor
  • Platelet-Derived Growth Factor: therapeutic use
  • Skin, Artificial
  • Wound Healing

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Authors

  • M Edmonds

  • M Bates

  • M Doxford

  • A Gough

  • A Foster

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free